Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

NCT02737774 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: Icotinib
DRUG: Pemetrexed/Carboplatin

Sponsor

Henan Cancer Hospital